Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO – Get Free Report) saw a significant decrease in short interest in July. As of July 15th, there was short interest totaling 4,548 shares, a decrease of 77.5% from the June 30th total of 20,244 shares. Approximately 0.2% of the company’s stock are short sold. Based on an average daily volume of 29,911 shares, the short-interest ratio is currently 0.2 days.
Cardio Diagnostics Stock Performance
CDIO stock opened at $1.55 on Friday. The firm has a 50 day simple moving average of $1.87 and a 200 day simple moving average of $2.18. Cardio Diagnostics has a 52 week low of $0.97 and a 52 week high of $7.91. The stock has a market cap of $4.59 million, a P/E ratio of -0.46 and a beta of 2.23.
Cardio Diagnostics (NASDAQ:CDIO – Get Free Report) last released its quarterly earnings data on Friday, May 15th. The company reported ($0.63) earnings per share for the quarter. Cardio Diagnostics had a negative net margin of 36,950.00% and a negative return on equity of 78.82%.
Analysts Set New Price Targets
Read Our Latest Stock Report on CDIO
Hedge Funds Weigh In On Cardio Diagnostics
Hedge funds have recently modified their holdings of the stock. Renaissance Technologies LLC purchased a new stake in shares of Cardio Diagnostics during the first quarter worth $30,000. Citadel Advisors LLC purchased a new position in Cardio Diagnostics in the third quarter valued at about $79,000. Finally, DRW Securities LLC increased its position in Cardio Diagnostics by 122.8% in the 4th quarter. DRW Securities LLC now owns 40,463 shares of the company’s stock worth $110,000 after purchasing an additional 22,298 shares during the last quarter. 8.06% of the stock is owned by institutional investors and hedge funds.
Cardio Diagnostics Company Profile
Cardio Diagnostics Holdings, Inc develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc was founded in 2017 and is headquartered in Chicago, Illinois.
Featured Stories
- Five stocks we like better than Cardio Diagnostics
- AMD and Cerbras Create A New Blueprint For Hardware
- Intel Earnings Reveal Whether the Chip Selloff Created a Buy
- CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test
- Plugging In: How Kinder Morgan Powers Up Profits
Receive News & Ratings for Cardio Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardio Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
